RECURSION PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Recursion Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Recursion Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 38.8 %, a 17.6% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 38.8 -8.28 -17.6% Jun 30, 2024
Q1 2024 41.6 -8.38 -16.8% Mar 31, 2024
Q4 2023 43.2 -7.46 -14.7% Dec 31, 2023
Q3 2023 44.1 +2.9 +7.04% Sep 30, 2023
Q2 2023 47 +18 +61.8% Jun 30, 2023
Q1 2023 50 +31.4 +169% Mar 31, 2023
Q4 2022 50.7 +35.2 +228% Dec 31, 2022
Q3 2022 41.2 +12.7 +44.5% Sep 30, 2022
Q2 2022 29.1 Jun 30, 2022
Q1 2022 18.6 Mar 31, 2022
Q4 2021 15.4 Dec 31, 2021
Q3 2021 28.5 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.